SK Biopharmaceuticals licenses Parkinson's candidate 1ST-104 in deal worth up to $314.8m
SK Biopharmaceuticals has secured exclusive global rights to 1ST Biotherapeutics' preclinical Parkinson's disease candidate 1ST-104 in a deal worth up to $314.8 million.
1ST-104 is an oral dual inhibitor of LRRK2 and c-Abl designed to target disease biology associated with Parkinson's progression rather than only managing symptoms.
The agreement also includes a $2.2 million strategic investment in 1ST Biotherapeutics and gives the developer potential milestone payments and royalties as the programme advances.
Field | Content |
Alert Type | Deal |
Companies | SK Biopharmaceuticals; 1ST Biotherapeutics |
Deal Type | Exclusive global licensing agreement |
Asset or Company | 1ST-104 |
Therapy Area(s) | Neurology; Parkinson's disease |
Technology or Modality | Oral dual LRRK2/c-Abl inhibitor |
Development Stage | Preclinical |
Deal Value | Up to US$314.8 million under the licence, plus a separate US$2.2 million strategic equity investment and royalties |
Geography | Worldwide |
What Happened | SK Biopharmaceuticals secured exclusive global rights to 1ST-104 from 1ST Biotherapeutics. |
Why It Matters | The programme targets two disease-associated signalling pathways and is intended as a potentially disease-modifying approach to Parkinson's disease. |
Supporting Context | LRRK2 and c-Abl have both been implicated in molecular processes associated with Parkinson's disease pathology and neurodegeneration. |
Strategic Rationale | SK Biopharmaceuticals expands its neuroscience pipeline while 1ST Biotherapeutics gains funding and access to a global development and commercialisation partner. |
Potential Impact | Successful development could introduce a new oral treatment designed to affect Parkinson's disease biology rather than symptoms alone. |
Key Takeaway | SK Biopharmaceuticals has licensed 1ST-104 globally in a transaction worth up to US$314.8 million. |
What to Watch | IND-enabling work, first-in-human development and early evidence of target engagement. |
Primary Source | 1ST Biotherapeutics / SK Biopharmaceuticals |
Relevant Date | 17 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios